| Ytd | -20.36% | |
| 1y | -64.63% |
| Open | 12.84 | Prev Close | 12.76 | Low | 12.29 | High | 12.97 | Mkt Cap | 198.30M |
| Vol | 287.50K | Avg Vol | 485.44K | EPS | -14.66 | P/E | N/A | Forward P/E | -0.01 |
| Beta | 2.08 | Short Ratio | 0.35 | Inst. Own | 0.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 12.73 | 200-d Avg | 16.21 | 1yr Est | 5.83 |
TNXP News
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluat
Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a
Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s
Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with
Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial paye
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides